Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
NervGen Pharma Corp.
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
April 7, 2026
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
March 13, 2026
←
Previous Page
1
2